Tejin Pharma has partnered with pharmaceutical company Aska Pharmaceutical to develop treatments for gynaecological diseases. 

As per the agreement, the companies will collaborate to accelerate the early-stage drug discovery process aimed at identifying innovative therapeutic candidates.  

The companies intend to develop novel small-molecule drug candidates, a process which typically begins with screening large numbers of compounds to identify ‘hit’ compounds that interact with specific molecular targets.  

The molecular structure of these ‘hits’ is then optimised to achieve the desired efficacy, pharmacokinetic properties, and safety profiles required for drug development. 

By combining Teijin Pharma’s computer-aided drug design (CADD) and AI-driven drug discovery technologies with Aska Pharmaceutical’s expertise in gynaecological diseases, the companies hope to increase the speed and success rate of the drug discovery process.